GERN Geron Corp
- Stocks
- Healthcare
- NASDAQ: GERN
Price (delayed)
$1.075
Market cap
$685.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$856.08M
Relative Growth:
Rel. Growth:
94
Relative Strength:
Rel. Strength:
7
Relative Valuation:
Rel. Valuation:
14
Relative Profitability:
Rel. Profitability:
43
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two
Highlights
Geron's EPS has soared by 64% YoY and by 38% from the previous quarter
The net income has soared by 60% YoY and by 37% from the previous quarter
The quick ratio has soared by 89% YoY but it has contracted by 2.6% from the previous quarter
GERN's debt has surged by 187% year-on-year
Geron's equity has decreased by 15% YoY and by 3.2% from the previous quarter
Key stats
What are the main financial stats of GERN
Market
Valuations
Earnings
Shares outstanding
638.02M
Market cap
$685.87M
Enterprise value
$856.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.64
Price to sales (P/S)
4.35
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.21
Revenue
$164.45M
Gross profit
$160.81M
Operating income
-$77.42M
Net income
-$88.01M
EBIT
-$59.54M
EBITDA
-$58.41M
Free cash flow
-$178.28M
Per share
Balance sheet
Liquidity
EPS
-$0.13
EPS diluted
-$0.13
Free cash flow per share
-$0.27
Book value per share
$0.41
Revenue per share
$0.25
TBVPS
$0.83
Total assets
$555.2M
Total liabilities
$295.67M
Debt
$249.81M
Equity
$259.53M
Working capital
$441.31M
Debt to equity
0.96
Current ratio
7.87
Quick ratio
6.68
Net debt/EBITDA
-2.91
Margins
Efficiency
Dividend
EBITDA margin
-35.5%
Gross margin
97.8%
Net margin
-53.5%
Operating margin
-47.1%
Return on assets
-16.3%
Return on equity
-32%
Return on invested capital
-10.2%
Return on capital employed
-12.1%
Return on sales
-36.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GERN stock price
How has the Geron stock price performed over time
Intraday
-1.38%
1 week
-13.31%
1 month
-16.02%
1 year
-74.82%
YTD
-69.63%
QTD
-21.53%
Financial performance
How have Geron's revenue and profit performed over time
Revenue
$164.45M
Gross profit
$160.81M
Operating income
-$77.42M
Net income
-$88.01M
Gross margin
97.8%
Net margin
-53.5%
The operating margin has soared by 100% year-on-year and by 59% since the previous quarter
GERN's net margin has surged by 100% year-on-year and by 55% since the previous quarter
The operating income has soared by 66% YoY and by 42% from the previous quarter
The net income has soared by 60% YoY and by 37% from the previous quarter
Price vs fundamentals
How does GERN's price correlate with its fundamentals
Growth
What is Geron's growth rate over time
Valuation
What is Geron stock price valuation
P/E
N/A
P/B
2.64
P/S
4.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.21
Geron's EPS has soared by 64% YoY and by 38% from the previous quarter
The P/B is 56% below the last 4 quarters average of 6.1 and 48% below the 5-year quarterly average of 5.1
Geron's equity has decreased by 15% YoY and by 3.2% from the previous quarter
The P/S is 100% below the 5-year quarterly average of 1577.7 and 88% below the last 4 quarters average of 36.6
The revenue has grown by 41% from the previous quarter
Efficiency
How efficient is Geron business performance
Geron's ROS has soared by 100% YoY and by 64% from the previous quarter
Geron's ROIC has soared by 85% YoY and by 56% from the previous quarter
The ROA has soared by 68% YoY and by 40% from the previous quarter
GERN's ROE has soared by 57% year-on-year and by 34% since the previous quarter
Dividends
What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GERN.
Financial health
How did Geron financials performed over time
Geron's total assets is 88% higher than its total liabilities
GERN's current ratio has soared by 118% year-on-year
The total liabilities has soared by 107% year-on-year
GERN's debt is 3.7% smaller than its equity
GERN's debt has surged by 187% year-on-year
Geron's equity has decreased by 15% YoY and by 3.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.